

Curriculum Vitae

Pierre Gantner, PharmD, PhD

Educational background and jobs

Since 2021	Assistant Professor , INSERM UMR-S1109 (Pr Samira Fafi-Kremer), Faculty of Medicine, & Medical Virology Laboratory, University Hospital of Strasbourg, Strasbourg, France
2019-2020	Post-doctoral fellow , Université de Montréal, Nicolas Chomont's laboratory (www.chomontlab.com), Montréal, QC, Canada
2015-2018	Medical fellow , Medical Virology Laboratory (Pr Samira Fafi-Kremer), University Hospital of Strasbourg, Strasbourg, France
2015-2018	PhD student , INSERM UMR_S1109 (Pr Samira Fafi-Kremer) Faculty of Medicine, Strasbourg, France
2013-2015	MSc student , Microbiology: option Virology (Pr Jade Ghosn), Faculty of Pharmacy, Paris-Sud, France

Other diplomas

2016-2017	University degree: Biostatistics (Bayesian inference), Faculty of Medicine, Strasbourg, France
2014	PharmD and post-graduate diploma in Hospital Pharmacy, Faculty of Pharmacy, Strasbourg, France
2012-2013	University degree: HIV-infection care, Faculty of Medicine, Paris-Est Créteil, France
2012-2013	University degree: Education thérapeutique du patient, Faculty of Medicine, Nancy, France
2011-2012	University degree: Antibiotherapy in an Hospital setting, Faculty of Medicine, Nancy, France
2010-2014	Medical Resident in Medical Biology, University Hospital of Strasbourg, France
2005-2009	Internship in Hospital Pharmacy, University Hospital of Strasbourg, France

Awards

2020	Young Investigator Scholarship, Conference on Retroviruses and Opportunistic Infections, Boston, MA.
2019	Post-doctoral fellowship award (3 years), Canadian Institutes of Health Research (CIHR) [Accepted]
2019	Post-doctoral fellowship award (2 years), Fonds de Recherche Québec – Santé (FRQ-S) [Declined]
2019	Young Investigator Grant, HIV Persistence Workshop, Miami, FL.
2018	Young Investigator Scholarship, Conference on Retroviruses and Opportunistic Infections, Boston, MA.
2017	Young Investigator Scholarship, Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
2014	Excellence award as the best MSc student – specialization Microbiology, Paris, France.

Administrative functions

Since 2015	Member of commission AC11/AC43 from Agence Nationale de Recherche sur la SIDA (ANRS)
Since 2012	Secretary of the Association : <i>Social – Alsace – VIH</i>

Teachings

2022-2023	Clayton Fuaa, MSc student, Université de Strasbourg
Since 2017	2h Unité d'enseignement de Virologie en Etudes odontologiques, Université de Strasbourg
Since 2016	2h Unité d'enseignement de Virologie en Etudes maïeutiques, Université de Strasbourg
Since 2016	4h Unité d'enseignement « Microbiologie Médicale », Master 1 de l'Université de Strasbourg
Since 2016	5h + 6h in Virologie Médicale et Fondamentale en 2 ^{ème} cycle des Etudes Médicales (Faculté de Médecine de Strasbourg)
Since 2016	6h (APP) en Virologie au DES de Biologie Médicale, Université de Strasbourg
Since 2010	5th year Pharmacy students (5 ^{ème} année hospitalo-universitaire)

Books

1. Chapter PreP et Prophylaxie post-exposition; **VIH, Hépatites et Santé sexuelle**; AFRAVIH, 2020.
2. Chapter Résistance aux antirétroviraux et persistance du VIH; **Recommandations de Prise en charge des personnes vivant avec le VIH** – Rapport Delobel; 2023

Publications

International journals

1. Gantner P, Koeppel C, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Priester M, Muret P, Sueur C, Fafi-Kremer S, Rey D. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. **Scand J Infect Dis** 2014; 46(12): 838-45.
2. Gantner P, Reinhart S, Partisani M, Baldeyrou M, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Priester M, Fafi-Kremer S, Muret P, Rey D. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study. **HIV Med** 2015; 16(2): 132-6.
3. Gantner P, Treger M, De Miscault C, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Partisani M, Priester M, Rey D. Predictors of standard follow-up completion after sexual exposure to HIV: Five-year retrospective analysis in a French HIV-infection care center. **Plos ONE** 2015; 10(12): e0145440.
4. Gantner P, Bani-Sadr F, Garraffo R, Roger PM, Jovelin T, Pugliese P, Rey D. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. **Plos ONE** 2016; 11(10): e0164240.
5. Gantner P, Morand-Joubert L, Sueur C, Raffi F, Fagard C, Lascoux-Combe C, Salmon D, Amiel C, Lambert-Niclot S, Fofana DB, Viard JP, Fafi-Kremer S, Rouzioux C, Avettand-Fenoel V, Ghosn J. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pre-treated patients who achieved sustained virological suppression. **J Antimicrob Chemother** 2016; 71(3):751-61.
6. Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D, Rouzioux C, Ghosn J. HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens. **J Antimicrob Chemother** 2016; 71(11): 3202-3205.
7. Lepiller Q, Solis M, Velay A, Gantner P, Sueur C, Stoll-Keller F, Barth H, Fafi-Kremer S. Problem-based learning in laboratory medicine resident education: a satisfaction survey. **Ann Biol Clin** 2017; 75(2): 181-192.
8. Gantner P, Velay A, Guigue N, Barth H, Wendling MJ, Fafi-kremer S. Performance of the Liaison® XL Murex recHTLV-I/II Immunoassay in the Detection of HTLV-1/2 Antibodies in Serum. **Clin Lab** 2017; 63(5): 997-1001.
9. Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. **HIV Med** 2017; 18(9): 704-708. (lettre à l'éditeur)
10. Gantner P, Mélard A, Damond F, Delaugerre C, Dina J, Gueudin M, Maillard A, Sauné K, Rodallec A, Tuillon E, Plantier JC, Rouzioux C, Avettand-Fenoel V. Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies. **J Med Virol** 2017; 89(11): 2047-2050.
11. Velay A, Solis M, Kack-Kack W, Gantner P, Maquart M, Martinot M, Augereau O, De Briel D, Kieffer P, Lohmann C, Poveda JD, Cart-Tanneur E, Argemi X, Leparç-Goffart I, de Martino S, Jaulhac B, Raguët S, Wendling MJ, Hansmann Y, Fafi-Kremer S. A new hot spot for tick-borne encephalitis (TBE): A marked increase of TBE cases in France in 2016. **Ticks Tick Borne Dis** 2018; 9(1): 120-125.

12. Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Beck-Wirth G, Faller J-P, Martinot M, Wainberg M, Fafi-Kremer S. Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. **J Antimicrob Chemother** 2018; 73(4): 1045-1053.
13. Gantner P, Barnig C, Partisani M, Beck-Wirth G, Faller JP, Martinot M, Mohseni-Zadeh M, Cheneau C, Batard M-L, Fischer P, Fuchs A, Uring-Lambert B, Bahram S, Rey D, Fafi-Kremer S. Distribution and reduction magnitude of HIV-DNA burden in CD4+ T-cell subsets depends on ART initiation timing. **AIDS** 2018; 32(7): 921-926.
14. Gantner P, Ghosn J. Genital reservoir: A barrier to functional cure? **Curr Opin HIV AIDS** 2018; 13(5): 395-401.
15. Gantner P, Cotte L, Allavena C, Bani-Sadr F, Huleux T, Duvivier C, Valantin M-A, Jacomet C, Joly V, Cheret A, Pugliese P, Delobel P, Cabié A, Rey D. Higher rates of HBsAg clearance with TDF-containing therapy in HBV/HIV coinfection. **PLoS ONE** 2019; 14(4): e0215464.
16. Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong MA, Duvivier C, Launay O, Kramochkine M, Arvieux C, Ménard A, Piroth L, Canestri A, Trias D, Peytavin G, Landman R, Ghosn J. "Real life" use of raltegravir during pregnancy in France: the Coferal-IMEA048 cohort study. **PLoS ONE** 2019; 14(4): e0216010.
17. Velay A, Paz M, Cesbron M, Gantner P, Solis M, Soulier E, Argemi X, Martinot M, Hansmann Y, Fafi-Kremer S. Tick-borne encephalitis virus: molecular determinants of neuropathogenesis of an emerging pathogen. **Crit Rev Microbiol** 2019; 45(4): 472-493.
18. Velay A, Solis M, Benotmane I, Gantner P, Soulier E, Moulin B, Caillard S, Fafi-Kremer S. Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. **Antimicrob Agents Chemother** 2019; 63(8). pii: e00393-19.
19. Solis M, Velay A, Gantner P, Bausson J, Filippattu A, Freitag R, Moulin B, Caillard S, Fafi-Kremer S. Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. **J Infect** 2019; 79(1): 56-60.
20. Gantner P, Hessamfar M, Souala MF, Valin N, Simon A, Ajana F, Bouvet E, Rouveix E, Cotte L, Bani-Sadr F, Hustache-Mathieu L, Lebrette MG, Truchetet F, Galempoix JM, Piroth L, Pellissier G, Muret P, Rey D; E/C/F/TAF PEP Study Group. Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis. **Clin Infect Dis** 2019. pii: ciz577.
21. Gantner P, Allavena C, Duvivier C, Cabié A, Reynes J, Makinson A, Ravaux I, Bréigeon S, Cotte L, Rey D. Factors associated with post-exposure prophylaxis (PEP) completion and condom use among PEP users in France, 2004-2017. **HIV Med** 2020; 27(7): 463-469.
22. Dufour C*, Gantner P*, Fromentin R, Chomont N. The multifaceted nature of HIV latency. **J Clin Invest** 2020; 130(7): 3381-3390.
- *Co-first author
23. Gantner P, Pagliuzza A, Pardons M, Ramgopal M, Routy JP, Fromentin R, Chomont N. Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. **Nat Commun** 2020; 11(1): 4089.
24. Loubaki L, Gantner P, Pagliuzza A, Fausther-Bovendo H, Kobinger G, Chomont N, Germain M. Testing for the presence of SARS-CoV-2 RNA in presymptomatic blood donors. **Transfusion** 2021; 61(2): 649-651.

25. Cole B, Lambrechts L, Gantner P, Noppe Y, Bonine N, Witkowski W, Chen L, Palmer S, Mullins JI, Chomont N, Pardons M, Vandekerckhove L. In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. **Nat Commun** 2021; 12(1): 3727.
26. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. **Nature** 2021; 596(7871) :276-280.
27. Martinot M, Carnein S, Kempf C, Gantner P, Gallais F, Fafi-Kremer S. Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination. **Clin Microbiol Infect** 2021: S1198-743X(21)00369-4.
28. Benotmane I, Gautier-Vargas G, Gallais F, Gantner P, Cognard N, Olagne J, Velay A, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, Fafi-Kremer S, Caillard S. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. **Am J Transplant** 2021: (in press).
29. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, Bayer S, Solis M, Laugel E, Reix N, Schneider A, Glady L, Panaget B, Collongues N, Partisani M, Lessinger JM, Fontanet A, Rey D, Hansmann Y, Kling-Pillitteri L, Schwartz O, De Sèze J, Meyer N, Gonzalez M, Schmidt-Mutter C, Fafi-Kremer S. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. **EBioMedicine** 2021; 71: 103561.
30. Brunet-Ratnasingham E*, Anand SP*, Gantner P*, Dyachenko A, Moquin-Beaudry G, Brassard N, Beaudoin-Bussièrès G, Pagliuzza A, Gasser R, Benlarbi M, Point F, Prévost J, Laumaea A, Niessl J, Nayrac M, Sannier G, Orban C, Messier-Peet M, Butler-Laporte G, Morrison DR, Zhou S, Nakanishi T, Boutin M, Descôteaux-Dinelle J, Gendron-Lepage G, Goyette G, Bourassa C, Medjahed H, Laurent L, Rébillard RM, Richard J, Dubé M, Fromentin R, Arbour N, Prat A, Larochelle C, Durand M, Richards JB, Chassé M, Tétreault M, Chomont N, Finzi A, Kaufmann DE. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. **Sci Adv** 2021; 7: eabj5629.
- *Co-first author
31. Gallais F, Gantner P, Planas D, Solis M, Bruel T, Pierre F, Soulier E, Rossolillo P, Fourati S, Sibilila J, Schwartz O, Fafi-Kremer S. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. **Front Immunol** 2022; 13: 790212.
32. Gantner P, Buranapraditkun S, Pagliuzza A, Dufour C, Pardons M, Mitchell JL, Kroon E, Sacdalan C, Tulmethakaan N, Pinyakorn S, Robb ML, Phanuphak N, Ananworanich J, Hsu D, Vasana S, Trautmann L, Fromentin R, Chomont N. HIV rapidly targets a diverse pool of CD4+ T cells to establish productive and latent infections. **Immunity** 2023; 56: 653-668.e5.
33. Fava C, Fafi-Kremer S, Gantner P. HIV rapidly targets a diverse pool of CD4+ T cells to establish productive and latent infections. **J Virus Erad** 2023; in press.

National journals

1. Gantner P, Riegel L, Reinhart S, Lindecker B, Paupart I, Revillon S, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Priester M, Rey D. Attentes des personnes vivant avec le VIH en 2013 : la difficulté dans le regard de l'autre. **La revue francophone internationale de recherche infirmière** 2015; 2(1): 79-89.

Oral communications

International conferences

1. Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D, Rouzioux C, Ghosn J. La détection intermittente d'ARN VIH-1 dans le liquide séminal est corrélée à la détection d'ADN VIH-1 dans les cellules du sperme mais pas à la présence de CMV dans le liquide séminal. **Conférence Internationale Francophone sur le VIH (AFRAVIH)**. 20-23 Avril 2016, Bruxelles, Belgique.
2. Gantner P, Pagliuzza A, Pardons M, Ramgopal M, Routy JP, Fromentin R, Chomont N. Single-cell TCR sequencing reveals that clonally expanded cells highly contribute to the inducible HIV reservoir during ART. **International Workshop on HIV persistence during therapy**. December 10-13, 2019, Miami, FL. Abstract OP 4.3.
3. Gantner P, Pagliuzza A, Pardons M, Ramgopal M, Routy JP, Fromentin R, Chomont N. TCR sequencing reveals clonal expansion of inducible reservoirs in specific subsets. **Conference on Retroviruses and Opportunistic Infections**. March 8-11, 2020, Boston, MA. Abstract 362.
4. Gantner P, Buranapraditkun S, Pardons M, Pagliuzza A, Fromentin R, Mitchell J, Kroon E, Pinyakorn S, Robb ML, Phanuphak N, Ananworanich J, Hsu D, Vasan S, Trautmann L, Chomont N. Infected cells are clonotypically diverse in blood and lymph nodes since Fiebig stage I. **Conference on Retroviruses and Opportunistic Infections**. March 6-10, 2021, Seattle, WA. Abstract 154.